Register Now
Course Information

About the Course

Twelve immunotherapy agents have been approved sine 2011 in a wide variety of cancers. Immune checkpoint blockade leads to a new spectrum of dysimmune toxicity requiring collaboration between oncologists, providers, and specialists to improve the understanding of the mechanism, diagnosis, and management of immune-related adverse events (irAEs). The goal of the program is to bring together a multidisciplinary group of clinicians to share expertise and improve the care of patients receiving immune checkpoint inhibitor therapies.

Specialists in dermatology, endocrinology, gastroenterology, oncology, internal medicine, rheumatology/immunology, nurses, nurse practitioners, physician assistants and residents/ fellows are invited to attend.

Learning Objectives

As a result of attending the course, the participant will be able to:

  • Describe the mechanism of action associated with checkpoint inhibitor therapies.
  • Identify the spectrum of immune-related adverse events that can occur with immune checkpoint inhibitor therapies.
  • Implement assessment criteria, diagnostic testing, and interventions to improve early identification and management of immune-related AEs.
  • Recognize the importance and necessity of the multidisciplinary approach in treatment of immune-related adverse events.